QuantHealth, an AI-powered drug development platform, announced today its partnership with Atropos Health, a leader in translating clinical data into high-quality, personalized, real-world evidence for care. QuantHealth will leverage Atropos Health’s federated data model of more than 300 million patient records to strengthen its trial outcome predictions and bring life-saving therapies to patients faster, improving point-of-care solutions.
Trials are often lengthy, expensive, and complex, resulting in 90 percent of drugs failing at the clinical stage. Failing to accurately predict responses to experimental therapies costs pharmaceutical companies an annual loss of $45 billion. QuantHealth is tackling these issues head-on, utilizing Atropos Health’s data to bring real-world evidence and AI-driven decision support to trial design, recruitment, and execution.
“Utilizing federated data models enhances our ability to set new accuracy standards for clinical trial simulations,” said Orr Inbar, CEO and Co-Founder of QuantHealth. “By joining the Atropos Evidence Network, our models will gain access to a large, high-quality dataset that updates in real-time, increasing the quality and relevance of the data that our trial simulations are trained on. Furthermore, by deploying our models on the network, we will be able to validate our models in real-time, on individual patients.”
By joining Atropos Health’s Evidence™ Network, QuantHealth will be able to deploy its AI models to the point of care and unlock new opportunities for its pharma customers.
“Translational medicine has always suffered from a broken feedback loop,” said Orr Inbar, CEO and Co-Founder of QuantHealth. “Pharma is privy to treatment decisions and patient outcomes only after the fact, and patients benefit from pharmaceutical research only years later once the drugs are approved. By deploying our models to the point of care, patients can be matched to trials not only based on their current eligibility status, but by their future eligibility status, as well as by their likelihood to benefit from the trial. This is a paradigm shift in drug development that brings us closer to precision trials, and precision medicine as a whole.”
In addition, this partnership opens opportunities for QuantHealth to forge new channel partnerships with pharmaceutical companies already in Atropos Health’s network, adding to its existing customer base.
“In an industry where it takes ten to fifteen years to develop one successful drug, the need for timely precision medicine and informed decision-making has never been greater,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “This partnership demonstrates the importance of interconnectivity and real-world data’s power in advancing the pharmaceutical industry. By enabling collaboration through our Evidence Network and creating new connections between healthcare data proprietors and clinical researchers, we create a new paradigm for the healthcare ecosystem to accelerate the research and development of life-saving therapies.”
QuantHealth’s partnership with Atropos Health builds on a recent milestone announcement. The company, which entered the U.S. market in 2022, has delivered more than 100 successfully simulated clinical trials, demonstrating 85 percent accuracy and generating $215 million in financial returns for 8 of the top 20 pharmaceutical companies.
